STOCK TITAN

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Elutia (Nasdaq: ELUT) has announced the upcoming debut of EluPro™, its new Antibiotic-Eluting BioEnvelope, at the Heart Rhythm Society's annual meeting (HRS 2025) in San Diego from April 25-27, 2025. The product is designed for cardiac implantable electronic devices (CIEDs) and neurostimulators.

EluPro features a proprietary biomatrix that naturally conforms around CIEDs, offering a softer alternative to synthetic options. The product combines a dual-antibiotic combination with a natural biomatrix that supports healing while reducing bacterial colonization. Dr. Kimberly Mulligan, GM and VP of Elutia's Cardiovascular Division, emphasized the product's innovative approach to CIED antibiotic envelope technology.

The company will showcase EluPro at booth #2418 at the San Diego Convention Center, offering hands-on experience with the product. Healthcare professionals can schedule meetings through the HRS 2025 meeting portal or contact ir@elutia.com.

Elutia (Nasdaq: ELUT) ha annunciato il prossimo debutto di EluPro™, il suo nuovo BioEnvelope Antibiotico-Eluente, durante il meeting annuale della Heart Rhythm Society (HRS 2025) a San Diego dal 25 al 27 aprile 2025. Il prodotto è progettato per dispositivi elettronici impiantabili cardiaci (CIED) e neurostimolatori.

EluPro presenta una biomatrice proprietaria che si adatta naturalmente attorno ai CIED, offrendo un'alternativa più morbida rispetto alle opzioni sintetiche. Il prodotto combina una combinazione di due antibiotici con una biomatrice naturale che supporta la guarigione riducendo la colonizzazione batterica. La Dott.ssa Kimberly Mulligan, GM e VP della Divisione Cardiovascolare di Elutia, ha sottolineato l'approccio innovativo del prodotto alla tecnologia degli involucri antibiotici per CIED.

L'azienda presenterà EluPro allo stand #2418 al Centro Congressi di San Diego, offrendo un'esperienza pratica con il prodotto. I professionisti della salute possono pianificare incontri tramite il portale del meeting HRS 2025 o contattare ir@elutia.com.

Elutia (Nasdaq: ELUT) ha anunciado el próximo debut de EluPro™, su nuevo BioEnvelope Eluyente de Antibióticos, en la reunión anual de la Heart Rhythm Society (HRS 2025) en San Diego del 25 al 27 de abril de 2025. El producto está diseñado para dispositivos electrónicos implantables cardíacos (CIED) y neuroestimuladores.

EluPro cuenta con una biomatriz propietaria que se adapta naturalmente alrededor de los CIED, ofreciendo una alternativa más suave a las opciones sintéticas. El producto combina una combinación de dos antibióticos con una biomatriz natural que apoya la curación mientras reduce la colonización bacteriana. La Dra. Kimberly Mulligan, GM y VP de la División Cardiovascular de Elutia, enfatizó el enfoque innovador del producto hacia la tecnología de envoltura antibiótica para CIED.

La empresa exhibirá EluPro en el stand #2418 en el Centro de Convenciones de San Diego, ofreciendo una experiencia práctica con el producto. Los profesionales de la salud pueden programar reuniones a través del portal de la reunión HRS 2025 o contactar a ir@elutia.com.

Elutia (Nasdaq: ELUT)는 2025년 4월 25일부터 27일까지 샌디에이고에서 열리는 심장 리듬 학회(HRS 2025)에서 새로운 항생제 방출 생체막인 EluPro™의 출시를 발표했습니다. 이 제품은 심장 이식 전자기기(CIED) 및 신경 자극기를 위해 설계되었습니다.

EluPro는 CIED 주위에 자연스럽게 적응하는 독점 생체 매트릭스를 특징으로 하여 합성 옵션에 비해 더 부드러운 대안을 제공합니다. 이 제품은 두 가지 항생제 조합과 치유를 지원하면서 박테리아의 군집화를 줄이는 자연 생체 매트릭스를 결합합니다. Elutia의 심혈관 부서의 GM 및 VP인 킴벌리 멀리건 박사는 CIED 항생제 생체막 기술에 대한 제품의 혁신적인 접근 방식을 강조했습니다.

회사는 샌디에이고 컨벤션 센터의 부스 #2418에서 EluPro를 전시하며 제품에 대한 실습 경험을 제공합니다. 의료 전문가는 HRS 2025 회의 포털을 통해 미팅을 예약하거나 ir@elutia.com으로 연락할 수 있습니다.

Elutia (Nasdaq: ELUT) a annoncé le prochain lancement de EluPro™, son nouveau BioEnvelope à libération d'antibiotiques, lors de la réunion annuelle de la Heart Rhythm Society (HRS 2025) à San Diego du 25 au 27 avril 2025. Le produit est conçu pour les dispositifs électroniques implantables cardiaques (CIED) et les neurostimulateurs.

EluPro présente une biomatrice propriétaire qui s'adapte naturellement autour des CIED, offrant une alternative plus douce par rapport aux options synthétiques. Le produit combine une combinaison de deux antibiotiques avec une biomatrice naturelle qui soutient la guérison tout en réduisant la colonisation bactérienne. Dr. Kimberly Mulligan, GM et VP de la division cardiovasculaire d'Elutia, a souligné l'approche innovante du produit en matière de technologie d'enveloppe antibiotique pour CIED.

L'entreprise présentera EluPro au stand #2418 au Centre de congrès de San Diego, offrant une expérience pratique avec le produit. Les professionnels de la santé peuvent planifier des réunions via le portail de la réunion HRS 2025 ou contacter ir@elutia.com.

Elutia (Nasdaq: ELUT) hat das bevorstehende Debüt von EluPro™, seinem neuen antibiotikafreisetzenden BioEnvelope, auf dem jährlichen Treffen der Heart Rhythm Society (HRS 2025) in San Diego vom 25. bis 27. April 2025 angekündigt. Das Produkt ist für implantierbare elektronische Herzgeräte (CIEDs) und Neurostimulatoren konzipiert.

EluPro verfügt über eine proprietäre Biomatrix, die sich natürlich um die CIEDs anpasst und eine weichere Alternative zu synthetischen Optionen bietet. Das Produkt kombiniert eine Kombination aus zwei Antibiotika mit einer natürlichen Biomatrix, die die Heilung unterstützt und gleichzeitig die bakterielle Besiedelung reduziert. Dr. Kimberly Mulligan, GM und VP der kardiovaskulären Abteilung von Elutia, betonte den innovativen Ansatz des Produkts in der Technologie der CIED-Antibiotika-Umhüllung.

Das Unternehmen wird EluPro am Stand #2418 im San Diego Convention Center präsentieren und eine praktische Erfahrung mit dem Produkt anbieten. Gesundheitsfachkräfte können über das HRS 2025-Meeting-Portal Meetings planen oder ir@elutia.com kontaktieren.

Positive
  • Introduction of innovative medical device product EluPro, expanding company's product portfolio
  • Product combines dual-antibiotic protection with improved handling characteristics
  • Strategic presence at major industry conference (HRS 2025) for product launch
Negative
  • None.

Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025

SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s annual meeting (HRS 2025). Attendees will have the opportunity to experience firsthand the soft, conforming feel of EluPro and discover how its natural biomatrix supports healing while delivering trusted antibiotics to reduce bacterial colonization.

Engineered for both performance and handling, EluPro features a proprietary biomatrix that drapes naturally around CIEDs, avoiding the rough, stiff feel often associated with synthetic alternatives. Combined with a trusted dual-antibiotic combination, EluPro offers physicians a solution designed for both efficacy and ease of use without compromise.

“We are thrilled to introduce EluPro at HRS 2025 and give clinicians the opportunity to feel the difference biology makes,” said Dr. Kimberly Mulligan, GM and VP of Elutia’s Cardiovascular Division. “With its soft, conforming biomatrix and proven antibiotics, EluPro represents a meaningful step forward in CIED antibiotic envelope technology.”

Elutia invites physicians and medical professionals to experience EluPro firsthand at booth #2418 at the San Diego Convention Center from April 25-27, 2025. Attendees interested in scheduling a meeting with Elutia during the conference may register through the HRS 2025 meeting portal here or contact ir@elutia.com.

Those unable to attend can contact Elutia to speak with a representative and learn more about how EluPro is redefining CIED protection.

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements contained in this press release include, without limitation, any statements we make regarding the potential for EluPro to represent a meaningful step forward in CIED antibiotic envelope technology. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: the risk that clinical research data may not match preclinical study data; our ability to successfully commercialize, market and sell our EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com

This press release was published by a CLEAR® Verified individual.


FAQ

What is Elutia's new EluPro BioEnvelope and when will it be launched?

EluPro is an Antibiotic-Eluting BioEnvelope for cardiac devices and neurostimulators, featuring a soft biomatrix with dual antibiotics. It will debut at HRS 2025 in San Diego, April 25-27, 2025.

How does ELUT's EluPro technology differ from existing synthetic alternatives?

EluPro uses a proprietary biomatrix that drapes naturally around devices, providing a softer, more conforming feel compared to the rough, stiff synthetic alternatives.

What are the key features of Elutia's EluPro CIED protection system?

EluPro combines a natural biomatrix with dual antibiotics to reduce bacterial colonization, support healing, and provide easier handling for physicians.

Where can healthcare professionals experience ELUT's new EluPro product?

Healthcare professionals can experience EluPro at booth #2418 at the San Diego Convention Center during HRS 2025, or contact Elutia directly for more information.
Elutia Inc.

NASDAQ:ELUT

ELUT Rankings

ELUT Latest News

ELUT Stock Data

111.98M
22.78M
6%
62.41%
0.17%
Medical Devices
Biological Products, (no Disgnostic Substances)
Link
United States
SILVER SPRING